Merck MRK announced that the FDA has accepted its supplemental new drug application (sNDA) seeking approval of its oral ...

We have a deep understanding of how to evaluate your condition and how select and combine treatments to get the best possible results — even for rare cancers that many doctors in the community never ...

Cancer Research UK, Cytovation, and the Norwegian Cancer Society collaborate to advance treatment for adrenocortical ...

Adrenal tumors, which can be benign or malignant, often require effective treatment options to manage symptoms and prevent complications. Ablation techniques have emerged as minimally invasive ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its Welireg oral cancer drug ... in and around the adrenal glands.

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...

The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic ...

Cushing’s syndrome, or hypercortisolism, is a condition caused by overproduction of cortisol — a hormone that regulates stress, metabolism, and immune response. While cortisol ...

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its Welireg oral cancer drug in patients with rare tumors that form in and around the ...